Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- No Correlation Between Drowsiness and Efficacy of 2nd-Generation Antihistamine Drugs: HIRS
September 30, 2011
- JPMA Head Says Industry Will Support Infrastructure Development for Innovative Drug Discovery
September 28, 2011
- JPMA Asks for Continued R&D Tax Credit System
September 26, 2011
- Continuation of Premium for New Drug Development to Depend on Effects on Drug Lag, Drug Development: Mr Shirakawa of Kenporen
September 26, 2011
- FY2010 Deficit 2nd-Biggest Ever: Kenporen
September 26, 2011
- Over 95% of Patients Agree to Investigational Use of Removed Tissues: NCC Chief Director Kayama
September 22, 2011
- FPMAJ Seeks Improved System for Orphan Drug Development, Request to Be Submitted Soon to Health Minister
September 20, 2011
- Discontinue Re-pricing Following Market Expansion: Mr Umeda of PhRMA
September 19, 2011
- NIBIO Project Making Progress in Discovery of Safety Biomarkers for Evaluating Drug Toxicity
September 19, 2011
- Keizai Doyukai’s Hasegawa Has Not Given Up on 5% Corporate Tax Cut
September 14, 2011
- FPMAJ Announces Its Basic Policy on Providing Info. on Drugs Used Off-label
September 13, 2011
- Mr Hasegawa of Keizai Doyukai Welcomes Incoming Noda Administration
September 12, 2011
- Sales of Class 1 OTC Drugs Recovering Since January 2010: JSMI
September 12, 2011
- JGA to Prepare Transparency GLs
September 6, 2011
- Gaining Piece of the Pie in Growing Market “Best for Fast Results”: Keizai Doyukai’s Hasegawa
September 6, 2011
- Legal Prescription Rate Hits Record High 63.1% in FY2010: JPA
September 5, 2011
- 1st Meeting of Asia Cooperation Conference to Be Held Next March
September 5, 2011
- Keeping Premium for New Drug Development Will Stimulate Drug Development, R&D Spending: PhRMA
September 5, 2011
- Industry Objects to Proposals that Would Expand Range of Drugs Subject to Re-pricing
September 5, 2011
- FPMAJ Proposes Setting NHI Prices for All Generics at or Above Minimum Statutory Prices
September 5, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…